Medicines A–Z
D
Status | Drug name | NICE TAs | Comments |
---|---|---|---|
Danazol capsules | Hereditary angiodema (off label) |
||
Danazol capsules | Hereditary angiodema (off-label). Red for patients initiated from August 2020. |
||
Danthron | Treatment of constipation in terminally ill patients |
||
Dantrolene capsules | |||
Dantrolene sodium | |||
Dapagliflozin | For treating Type 2 diabetes in line with NICE |
||
Dapagliflozin (Forxiga®) | |||
Dapagliflozin | |||
Dapagliflozin | Specialist centres only for treating Type 1 diabetes |
||
Daratumumab |
|
Hospital use only |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.